Sepsis Emulsion Therapy Targeting Lipid Thresholds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sepsis, including intravenous fluids, antibiotics, and steroids, have shown limited success, particularly in reducing mortality rates, and existing emulsion therapies like GR270773 have demonstrated no efficacy in certain patient populations, leaving a significant unmet medical need.
Innovation Solution
Administering an intravenous emulsion comprising a phospholipid, a neutral lipid, and a cholate salt, specifically formulated to include 80-90% phospholipid, 5-10% neutral lipid, and 5-10% cholate salt, to patients with serum albumin levels of at least 1.5 g/dL and total cholesterol or high-density lipoprotein levels of at least 20 mg/dL, to effectively clear sepsis-causing toxins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If emulsion therapy (GR270773) is administered to all sepsis patients, then treatment coverage is maximized, but efficacy is lost because the emulsion shows no benefit in the overall population
Solution Approach 1:
The patent segments the sepsis patient population into subgroups based on baseline lipid panel characteristics (albumin ≥1.5 g/dL, total cholesterol ≥40 mg/dL, HDL ≥20 mg/dL). This segmentation identifies a specific subgroup that responds benefitfully to emulsion therapy, resolving the contradiction by applying treatment selectively rather than universally, thereby maintaining efficacy while adapting to patient-specific characteristics.
2Reliability
If conventional treatments (intravenous fluids, antibiotics, steroids) are used, then standard care protocols are followed, but mortality reduction is insufficient
Solution Approach 1:
The patent introduces a novel parameter-based selection criterion (lipid panel thresholds) to identify patients who will respond to emulsion therapy. This parameter change transforms the treatment approach from universal conventional care to targeted therapy based on specific biochemical parameters, thereby improving mortality reduction potential without compromising treatment availability for the identified subgroup.
3Reliability
If emulsion therapy is restricted to patients with specific lipid panel levels, then treatment efficacy is improved in selected patients, but the complexity of patient selection increases
Solution Approach 1:
The patent utilizes routinely collected clinical data (baseline lipid panel results) that are already part of standard patient workup. By leveraging these existing self-reported parameters, the selection process integrates seamlessly into常规 clinical practice without requiring additional complex testing or procedures, thereby improving treatment benefit while minimizing added complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The emulsion therapy achieves a mortality reduction of 8.2% to 16.7% in selected patient subpopulations, surpassing the desired 5% benefit criteria and demonstrating significant relative benefits in reducing sepsis-related deaths.
Implementation Method 1
emulsions of various materials, which showed efficacy in treatment of endotoxemia... The emulsions contain a phospholipid (phosphatidylcholine), a neutral lipid (triglyceride), and a cholate salt (sodium cholate)
Implementation Method 2
The emulsions contain... a cholate salt (sodium cholate)... to effectively clear sepsis-causing toxins
Data Source
AI summary
The invention relates to a method for treating sepsis in subjects who exhibit serum albumin levels, and one of total cholesterol or HDL levels, above minimum threshold values. The method involves intravenous administration of an emulsion, which contains a phospholipid, a neutral lipid, and a cholate salt.